---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-053502"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T04:51:30.798945+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics appoints John Doyle as CFO effective May 1, 2023

## Summary
- John Doyle appointed CFO effective May 1; succeeds interim CFO Andrew Einhorn, who serves until May 15.
- Base salary $415k, target bonus 40%, signing bonus $40k; equity grants: 109,824 options and 109,824 RSUs vesting over 4 years.
- Prior roles include CFO of 4D Pharma and Chiasma, VP Finance at Verastem Oncology.
- Severance: 9 months base salary on termination without cause; 12 months on change in control plus accelerated equity vesting.

## SEC filing metadata
- accession: 0001104659-23-053502
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465923053502/0001104659-23-053502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465923053502/tm2314004d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-053502
- JSON: https://secwatch.observer/filing/0001104659-23-053502.json
- Plain text: https://secwatch.observer/filing/0001104659-23-053502.txt

## Key facts
- Executive change
  Andrew Einhorn departed as Interim Chief Financial Officer at COGNITION THERAPEUTICS INC.
  - Action: departing
  - Role: Interim Chief Financial Officer
  source text: Mr. Doyle will succeed Mr. Andrew Einhorn, who has served as the Company’s Interim Chief Financial Officer since August 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465923053502/0001104659-23-053502-index.htm
- Executive change
  John Doyle was appointed as Chief Financial Officer at COGNITION THERAPEUTICS INC.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 1, 2023, Cognition Therapeutics, Inc. (the “ Company ”) announced the appointment of John Doyle as Chief Financial Officer of the Company, effective May 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465923053502/0001104659-23-053502-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.